Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-centre, open-label, parallel-group randomised controlled trial of disease-modifying anti-rheumatic drug (DMARD) dose maintenance (USUAL CARE) vs DMARD discontinuation after reduction (STOP) in adult patients with rheumatoid arthritis and psoriatic arthritis on stable biologic or targeted synthetic (b/ts) DMARD therapy +/- conventional synthetic (cs)DMARD/s, who are in sustained low disease activity at baseline

Next Previous
Search
Trial Profile

A multi-centre, open-label, parallel-group randomised controlled trial of disease-modifying anti-rheumatic drug (DMARD) dose maintenance (USUAL CARE) vs DMARD discontinuation after reduction (STOP) in adult patients with rheumatoid arthritis and psoriatic arthritis on stable biologic or targeted synthetic (b/ts) DMARD therapy +/- conventional synthetic (cs)DMARD/s, who are in sustained low disease activity at baseline

Status: Not yet recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Abatacept (Primary) ; Adalimumab (Primary) ; Azathioprine (Primary) ; Baricitinib (Primary) ; Certolizumab pegol (Primary) ; Etanercept (Primary) ; Golimumab (Primary) ; Hydroxychloroquine (Primary) ; Infliximab (Primary) ; Infliximab (Primary) ; Ixekizumab (Primary) ; Leflunomide (Primary) ; Methotrexate (Primary) ; Secukinumab (Primary) ; Sulfasalazine (Primary) ; Tocilizumab (Primary) ; Tofacitinib (Primary) ; Upadacitinib (Primary)
  • Indications Psoriatic arthritis; Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms PROSPECT

    • Most Recent Events

    • 16 Mar 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top